PUBLISHER: Frost & Sullivan | PRODUCT CODE: 1844018
PUBLISHER: Frost & Sullivan | PRODUCT CODE: 1844018
Emerging Therapeutics for Neurodegenerative Diseases, Global, 2025-2030
Innovative Strategies Driving the Future of Neuro Diseases
This report is a thorough examination of the current and future face of therapy for neurodegenerative diseases, such as Alzheimer's and Parkinson's. It articulates important growth drivers (e.g., precision medicine, AI paradigm for diagnostics, and the transformational megatrends of aging populations) and barriers they will face (e.g., the nature of competition and geopolitical upheaval).
The report will examine emerging therapeutic modalities including biologics (monoclonal antibodies and nucleic acid therapies), small molecules (amyloidogenesis inhibitors and NMDA antagonists), and alternative therapies (clinical nutraceuticals and microbiome). It also examines essential strategies such as convergence and disruption, as well as pipeline reviews of major emerging drugs and devices from prominent academic and industry participants. It pinpoints high-growth opportunities, such as disease-modifying therapies, immunotherapy drug products, and precision medicine along with funding trends and collaborations with strategic partners.
The study integrates technological, clinical, and market trends to provide actionable recommendations to stakeholders and emphasize the high-growth, multitrillion-dollar opportunities in the emerging neurodegenerative therapeutics space.
Table of Contents
Emerging Therapeutics for Neurodegenerative Diseases, Global, 2025-2030
Strategic Imperatives
- Why Is It Increasingly Difficult to Grow?
- The Strategic Imperative 8
- The Impact of the Top 3 Strategic Imperatives on Emerging Therapeutics for Neurodegenerative Diseases
- Growth Opportunities Fuel the Growth Pipeline Engine
- Research Methodology
Growth Opportunity Analysis
- Scope of Analysis
- Segmentation
Growth Generator
- Growth Drivers
- Growth Restraints
Emerging Therapies to Address Neurodegenerative Diseases
- Neurodegenerative Diseases: Facts and Challenges
- Understanding the Most Prevalent and Impactful Disorders of the Aging Brain
- Alzheimer's and Parkinson's Diseases Are the Leading Neurodegenerative Disorders
- Neurodegenerative Diseases: Emerging Therapies Under Biologics
- Mechanism and Clinical Applications: Nucleic Acid Therapies
- Mechanism and Clinical Applications: Monoclonal Antibodies
- Mechanism and Clinical Applications: Microbiome-Based Therapies
- Neurodegenerative Diseases: Emerging Therapies Under Small Molecules
- Mechanism and Clinical Applications: Amyloidogenesis Inhibitors
- Mechanism and Clinical Applications: NMDA Receptor Antagonist
- Mechanism and Clinical Applications: Cholinesterase Inhibitors
- Neurodegenerative Diseases: Alternative Therapies
- Mechanism and Clinical Applications: Nutraceuticals
- Mechanism and Clinical Applications: Ayurvedic and Traditional Practices
Innovation Landscape: Clinical Pipeline Overview For Alzheimer's and Parkinson's Disease
- Clinical Pipeline Overview for Alzheimer's
- Clinical Pipeline Innovator Profiles
- Clinical Pipeline Overview for Parkinson's
- Clinical Pipeline Innovator Profiles
Funding, Partnerships, and Acquisitions
- Funding Analysis
- Key Partnerships and Acquisitions
Outlook
- Innovative Biologic Delivery Systems Outlook
- Target-Specific Monoclonal Antibodies Outlook
- Gene Therapy and Genetic Engineering Outlook
Growth Opportunity Universe For Neurodegenerative Diseases
- Growth Opportunity 1: Advancements in Precision Medicine and Personalized Therapies
- Growth Opportunity 2: Breakthroughs in Disease-Modifying Therapies
- Growth Opportunity 3: Advancing Immunotherapeutic Approaches
Next Steps
- Benefits and Impacts of Growth Opportunities
- Next Steps
- Legal Disclaimer
